Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC

Immune checkpoint inhibitor (ICI) therapy has achieved remarkable clinical benefit in melanoma and non-small cell lung cancer (NSCLC). Tumor mutational signatures are the fingerprints of endogenous and exogenous factors that have acted throughout tumorigenesis and heterogeneity; however, their assoc...

Full description

Bibliographic Details
Main Authors: Wei Chong, Zhe Wang, Liang Shang, Shengtao Jia, Jin Liu, Zhen Fang, Fengying Du, Hao Wu, Yang Liu, Yang Chen, Hao Chen
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253120303450